These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26253589)

  • 1. [Current immunotherapy of multiple sclerosis].
    Paul F; Ruprecht K
    Nervenarzt; 2015 Aug; 86(8):1031-42; quiz 1043-4. PubMed ID: 26253589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying agents in multiple sclerosis.
    O'Connor PW; Oh J
    Handb Clin Neurol; 2014; 122():465-501. PubMed ID: 24507532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current treatment of multiple sclerosis].
    Gout O; Bensa C; Assouad R
    Rev Med Interne; 2010 Aug; 31(8):575-80. PubMed ID: 20579785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of relapsing-remitting multiple sclerosis.
    Tanasescu R; Ionete C; Chou IJ; Constantinescu CS
    Biomed J; 2014; 37(2):41-9. PubMed ID: 24732658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological Aspects of Approved MS Therapeutics.
    Rommer PS; Milo R; Han MH; Satyanarayan S; Sellner J; Hauer L; Illes Z; Warnke C; Laurent S; Weber MS; Zhang Y; Stuve O
    Front Immunol; 2019; 10():1564. PubMed ID: 31354720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapies for multiple sclerosis : review and update].
    Havla J; Kümpfel T; Hohlfeld R
    Internist (Berl); 2015 Apr; 56(4):432-45. PubMed ID: 25720530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].
    ; Rieckmann P
    Nervenarzt; 2006 Dec; 77(12):1506-18. PubMed ID: 17136556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New management algorithms in multiple sclerosis.
    Sorensen PS
    Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biological treatment of multiple sclerosis].
    Sørensen PS; Sellebjerg F
    Ugeskr Laeger; 2008 Jun; 170(24):2156-9. PubMed ID: 18565303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis research: diagnostics, disease-modifying treatments, and emerging therapies.
    Costello K
    J Neurosci Nurs; 2013 Dec; 45(6 Suppl 1):S14-23. PubMed ID: 24217187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.
    Rommer PS; Zettl UK; Kieseier B; Hartung HP; Menge T; Frohman E; Greenberg BM; Hemmer B; Stüve O
    Clin Exp Immunol; 2014 Mar; 175(3):397-407. PubMed ID: 24102425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Mar; 63(1620):42-48. PubMed ID: 33976089
    [No Abstract]   [Full Text] [Related]  

  • 19. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
    Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G
    Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multiple sclerosis - success from bench to bedside.
    Tintore M; Vidal-Jordana A; Sastre-Garriga J
    Nat Rev Neurol; 2019 Jan; 15(1):53-58. PubMed ID: 30315270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.